Wockhardt Yönetim

Yönetim kriter kontrolleri 4/4

Wockhardt CEO'su Murtaza Khorakiwala, Apr2009 tarihinde atandı, in görev süresi 15.58 yıldır. in toplam yıllık tazminatı ₹ 21.20M olup, şirket hissesi ve opsiyonları dahil olmak üzere 95.3% maaş ve 4.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.18% ine doğrudan sahiptir ve bu hisseler ₹ 362.69M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 15.6 yıl ve 7.5 yıldır.

Anahtar bilgiler

Murtaza Khorakiwala

İcra Kurulu Başkanı

₹21.2m

Toplam tazminat

CEO maaş yüzdesi	95.3%
CEO görev süresi	15.6yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	15.6yrs
Yönetim Kurulu ortalama görev süresi	7.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Murtaza Khorakiwala'un ücretlendirmesi Wockhardt'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-₹3b
Jun 30 2024	n/a	n/a	-₹3b
Mar 31 2024	₹21m	₹20m	-₹5b
Dec 31 2023	n/a	n/a	-₹5b
Sep 30 2023	n/a	n/a	-₹5b
Jun 30 2023	n/a	n/a	-₹6b
Mar 31 2023	₹24m	₹23m	-₹6b
Dec 31 2022	n/a	n/a	-₹6b
Sep 30 2022	n/a	n/a	-₹5b
Jun 30 2022	n/a	n/a	-₹3b
Mar 31 2022	₹24m	₹17m	-₹2b
Dec 31 2021	n/a	n/a	-₹787m
Sep 30 2021	n/a	n/a	-₹567m
Jun 30 2021	n/a	n/a	-₹867m
Mar 31 2021	₹24m	₹24m	-₹3b
Dec 31 2020	n/a	n/a	-₹2b
Sep 30 2020	n/a	n/a	-₹3b
Jun 30 2020	n/a	n/a	-₹3b
Mar 31 2020	₹24m	₹24m	-₹2b
Dec 31 2019	n/a	n/a	-₹1b
Sep 30 2019	n/a	n/a	-₹2b
Jun 30 2019	n/a	n/a	-₹2b
Mar 31 2019	₹24m	₹24m	-₹3b
Dec 31 2018	n/a	n/a	-₹3b
Sep 30 2018	n/a	n/a	-₹3b
Jun 30 2018	n/a	n/a	-₹3b
Mar 31 2018	₹24m	₹19m	-₹6b

Tazminat ve Piyasa: Murtaza 'nin toplam tazminatı ($USD 251.05K ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 481.61K ).

Tazminat ve Kazançlar: Murtaza 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Murtaza Khorakiwala (51 yo)

15.6yrs

Görev süresi

₹21,200,000

Tazminat

Dr. Murtaza Habil Khorakiwala serves as the Managing Director of Wockhardt Ltd. since April 2009 and has been its Executive Director since March 31, 2009. Dr. Khorakiwala serves as a Director of Khorakiwal...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Habil Khorakiwala	Founder & Executive Chairman	20.8yrs	₹36.50m	0.37% ₹ 736.7m
Murtaza Khorakiwala	MD & Executive Director	15.6yrs	₹21.20m	0.18% ₹ 362.7m
Huzaifa Khorakiwala	Executive Director	15.6yrs	₹21.20m	0.17% ₹ 346.3m
Deepak Madnani	Chief Financial Officer	2.4yrs	Veri yok	0.0080% ₹ 16.0m
Mahesh Patel	Chief Scientific Officer of New Drug Discovery	no data	₹1.71m	0.036% ₹ 71.9m
Debolina Partap	Senior Vice President of Legal	no data	Veri yok	0.0077% ₹ 15.5m
Neeraj Agarwal	Chief Human Resource Officer	no data	Veri yok	Veri yok
Anil Kamath	Senior Vice President of Business Development	no data	₹1.61m	Veri yok
Zoher Sihorwala	Head of Global Regulatory Affairs	10.8yrs	Veri yok	Veri yok
Prakash Gupta	President of Supply Chain	no data	Veri yok	Veri yok
Ravindra Limaye	Managing Director of Wockhardt UK	no data	Veri yok	Veri yok
Lalit Aggarwal	President of Manufacturing	no data	Veri yok	Veri yok

15.6yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: 532300 'un yönetim ekibi deneyimli ve deneyimlidir ( 15.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Habil Khorakiwala	Founder & Executive Chairman	20.8yrs	₹36.50m	0.37% ₹ 736.7m
Murtaza Khorakiwala	MD & Executive Director	15.7yrs	₹21.20m	0.18% ₹ 362.7m
Huzaifa Khorakiwala	Executive Director	15.6yrs	₹21.20m	0.17% ₹ 346.3m
Akhilesh Krishna Gupta	Non-Executive Independent Director	4.3yrs	₹1.10m	Veri yok
Vinesh Jairath	Non-Executive & Independent Director	8yrs	₹1.70m	Veri yok
Zahabiya Khorakiwala	Non-Executive Non- Independent Director	7.1yrs	₹300.00k	Veri yok
Ahmad Javed	Non Executive Independent Director	less than a year	Veri yok	0.00012% ₹ 240.5k
Amelia Fernandes	Independent Director	1.3yrs	₹1.00m	0.000060% ₹ 120.2k

7.5yrs

Ortalama Görev Süresi

66.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 532300 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.5 yıldır).

Wockhardt Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Wockhardt Limited, Annual General Meeting, Jun 28, 2024

Wockhardt Limited Appoints Ahmad Javed as Additional (Independent) Director

Wockhardt Limited Announces Cessation of Independent Directors

Insufficient new directors

Wockhardt Limited, Annual General Meeting, Aug 14, 2023

Insufficient new directors

Recent updates

Second quarter 2025 earnings released: ₹1.47 loss per share (vs ₹5.37 loss in 2Q 2024)

Wockhardt Limited to Report First Half, 2025 Results on Nov 13, 2024

Wockhardt Limited has filed a Follow-on Equity Offering.

Wockhardt's Miqnaf (Nafithromycin) Receives Favourable Recommendation from Subject Expert Committee of Central Drugs Standard Control Organization

Wockhardt's WCK 6777 Receives Fast Track Designation by US FDA, Completes Phase I Study

First quarter 2025 earnings released: ₹0.95 loss per share (vs ₹9.28 loss in 1Q 2024)

Wockhardt Limited to Report Q1, 2025 Results on Aug 09, 2024

Wockhardt Limited, Annual General Meeting, Jun 28, 2024

Wockhardt Limited Appoints Ahmad Javed as Additional (Independent) Director

Full year 2024 earnings released: ₹32.05 loss per share (vs ₹38.80 loss in FY 2023)

Wockhardt Limited to Report Q4, 2024 Results on May 28, 2024

Wockhardt Limited Announces Cessation of Independent Directors

Wockhardt Limited has completed a Follow-on Equity Offering in the amount of INR 4.800429 billion.

New minor risk - Shareholder dilution

Wockhardt Limited has filed a Follow-on Equity Offering.

Wockhardt Limited has filed a Follow-on Equity Offering.

Third quarter 2024 earnings released: ₹5.75 loss per share (vs ₹6.62 loss in 3Q 2023)

New minor risk - Share price stability

Second quarter 2024 earnings released: ₹5.37 loss per share (vs ₹13.15 loss in 2Q 2023)

Insufficient new directors

Wockhardt Limited to Report Q1, 2024 Results on Aug 14, 2023

Wockhardt Limited, Annual General Meeting, Aug 14, 2023

Wockhardt Limited to Report Q4, 2023 Results on May 26, 2023

Third quarter 2023 earnings released: ₹6.62 loss per share (vs ₹0.61 loss in 3Q 2022)

Wockhardt Limited to Report Q3, 2023 Results on Feb 13, 2023

Insufficient new directors

Second quarter 2023 earnings released: ₹13.15 loss per share (vs ₹3.03 profit in 2Q 2022)

Wockhardt Announces Successful Initiation of Global Phase 3 Clinical Study of Its Novel Antibiotic WCK 5222

Wockhardt Limited to Report Q1, 2023 Results on Aug 12, 2022

Wockhardt Limited, Annual General Meeting, Aug 12, 2022

Wockhardt Limited Announces Chief Financial Officer Changes

Full year 2022 earnings released

Insufficient new directors

Wockhardt Limited to Report Q4, 2022 Results on May 30, 2022

Wockhardt Limited Announces Chief Financial Officer Changes

Wockhardt Gets CDSCO Nod for Exporting Up to 100 Million Doses of Sputnik Vaccines

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Second quarter 2022 earnings released: EPS ₹3.03 (vs ₹0.32 in 2Q 2021)

Board Member recently bought ₹4.4m worth of stock

Company Secretary & Compliance Officer Gajanand Sahu has left the company

Full year 2021 earnings released: ₹27.02 loss per share (vs ₹14.79 loss in FY 2020)

Insider recently sold ₹20m worth of stock

Full year 2021 earnings released: ₹27.02 loss per share (vs ₹14.79 loss in FY 2020)

UK Government Announces Covid-19 Vaccination Contract Extension with Wockhardt

Third quarter 2021 earnings released: EPS ₹1.38 (vs ₹0.87 in 3Q 2020)

Wockhardt Limited to Report Q3, 2021 Results on Jan 29, 2021

New 90-day high: ₹551

Insider recently sold ₹1.6m worth of stock

New 90-day high: ₹487

New 90-day high: ₹393

First quarter earnings released

Wockhardt Limited to Report Q1, 2021 Results on Aug 29, 2020

New 90-day high - ₹303

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş